stockrow
Saturday 7 November 2026
Export HURA’s income statement to Excel — free account
TuHURA Biosciences, Inc.
HURA Healthcare Biotechnology
- EPS
- +33.3%
- Free cash flow
- −70.5%
Quarter to June 2026, against a year earlier
1.63
0.02
+1.24%
Follow HURA
Alert me
TuHURA Biosciences, Inc. (HURA) P/E ratio
TuHURA Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NBP NovaBridge Biosciences compare | n/m |
| VYGR Voyager Therapeutics, Inc. compare | n/m |
| IMUX Immunic, Inc. compare | n/m |
| AVXL Anavex Life Sciences Corp. compare | n/m |
| OTLK Outlook Therapeutics, Inc. compare | n/m |
| HURA TuHURA Biosciences, Inc. | n/m |
| ANIX ANIXA BIOSCIENCES INC compare | n/m |
| NRXP NRx Pharmaceuticals, Inc. compare | n/m |
| OKUR OnKure Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)